PCRX News and Press, Pacira BioSciences Inc. From 05/12/22

TAMPA, Fla., May 12, 2022 (GLOBE NEWSWIRE) --  Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales for EXPAREL ® (bupivacaine lipo...

Pacira BioSciences, Inc. (PCRX) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Susan Mesco – Head-Investor Relations Dave Stack – Chairman and Chief Executive Officer Charlie Reinhart – Chief Financial Officer Conference Call Participants Dav...

Pacira BioSciences press release (NASDAQ:PCRX): Q1 Non-GAAP EPS of $0.64 misses by $0.19. Revenue of $158M (+32.8% Y/Y) beats by $2.92M. Adjusted EBITDA was $53.8 million, or $1.20 per share (basic) and $1.16 per share (diluted) in the first quarter of 2022, compared to $36.2 million, or $0.8...

-- First quarter revenue of $158 million, up 33% over prior year -- -- Strong topline performance delivers net income and significantly positive adjusted EBITDA -- -- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., May 04, 2022 (GLOBE NEWSWIRE) -- Pacira BioScience...

Rengenxbio (NASDAQ: RGNX) , Corcept Therapeutics (NASDAQ: CORT) , and Pacira BioSciences (NASDAQ: PCRX) are all small-cap healthcare stocks with market caps below $3.5 billion. While the share prices of many companies in this sector have plummeted recently, these...

TAMPA, Fla., April 27, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets on Wednesday, May 4, 2022. Following the release, the company will host a live conference call a...

ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Small cap growth stocks entered bear market territory dur...

Pacira BioSciences (NASDAQ:PCRX) on Tuesday has announced preliminary revenue estimate of $157.4-$158.4M for Q1 2022, up from $119M revenue reported last year. It includes: EXPAREL product sales, $129.2M; ZILRETTA product revenue following Flexion Therapeutics acquisition, $23-$24M; and&...

TAMPA, Fla., April 12, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary revenues of $157.4 to $158.4 million for the first quarter of 2022, comp...

TAMPA, Fla., April 05, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 21 st Annual Needham Virtual Healthcare Conference at 8:45 AM ET on Tuesday, April 12, 2022. Live audio of the even...